Zelira Therapeutics : 2021 Annual General Meeting Presentation

onlyZELIRA THERAPEUTICS

A Global Biopharmaceutical Company Developing and Marketing Clinically Validated useCannabinoid-Based Medicines

AGM 13 JANUARY 2022

ersonalASX: ZLD

OTCQB:ZLDAF

zeliratx.com

Disclaimer & Important Notice

Disclaimer

onlyThis presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 ("Company"). It doesnot purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of it sofficers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the availability of any estimates, forecasts o projections set out in

usethis presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update,amend or supplement the informa Konatany Kme in its absolute discretion(without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments

ersonalCommission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is,to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company

PAGE 2

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

Your Board

only	GLOBAL

Dr. Oludare Odumosu CEO & Managing Director

• Post-clinicaldevelopment of Iroko Pharmaceutical's Zorvolex® Tivorbex® and Vivlodex® through FDA approvals and successful US market commercialization.
• Founding COO of Ilera Healthcare. Ilera Healthcare was acquired by TerrAscend (TER.CN) for $225 Mid 2019. Founding CSO/EVP of Ilera Therapeutics.

USA

use

Osagie Imasogie Chairman

• Over 30 years in the field of law, finance, business management, healthcare and the pharmaceutical industry.
• Founder and VP for Glaxo Smith Kline ("GSK") Ventures.
• Co-founderand the Senior Managing Partner of PIPV Capital, a Private Equity Firm focused on the Life Sciences vertical.
• Chairman and Founder of Ilera Healthcare, Ilera Therapeutics, iCeutica Inc., Churchill Pharma, Ception Therapeutics Inc. and Trigenesis Therapeutics Inc.

Lisa Gray Director

• Served as COO for Glaxo Smith Kline ("GSK") Ventures.
• Co-Founderand Vice Chair of Ilera Healthcare, and lead on the sale of this business to TerrAscend.
• Vice Chair for Ilera Holistic Healthcare and Ilera Therapeutics.
• Co-Founderand Managing Partner of PIPV Capital.

	AUSTRALIA
PAGE 3
ersonal

Harry Karelis Vice Chairman

• Founding Director/Shareholder of numerous ASX-listed companies including in the global medicinal cannabis sector.
• +25 years corporate/finance experience, specialising in med-tech private equity investing.
• Co-foundercorporate advisory & investment firm Gemelli Group.

Jason Peterson Director

• Founder, Director and Head of Corporate at Stock Broking and Corporate Advisory firm, CPS Capital.
• Founding Director/Shareholder of numerous ASX-listed companies including in the global medicinal cannabis sector.
• +25 years of experience in the financial advisory sector.

VOTING

How to Vote

When the poll is open, select the onlyvote icon at the top of the screen

useTo vote, select either For, Against or Abstain

You will see a vote confirmation

ersonalTo change or cancel your vote "click here to change your vote" at any time until

the poll is closed

PAGE 4

Broadcast	Vote	Q&A	Documents

Items of business

2A Re-elect Mr Sam Sample as a Director

FOR	AGAINST	ABSTAIN

2B Re-elect Mrs Jane Citizen as a Director

We have received your vote for

Click here to change your vote

	QUESTIONS
	How to ask a Question
only	To ask a written question select the
Q & A icon
		Broadcast	Vote	Q&A	Documents
use		Your question(s)
Select the topic your question relates	You may enter a question using the field below
	to from the drop-down list	Select Topic
ersonal		Questions are limited to 2,000 characters
Type your question in the text box and
	press the send button
				0 Character(s)	Send
PAGE 5

To ask a verbal question follow the instructions below the broadcast window.